Expedition Therapeutics

Redefining Care.

San Francisco, United States · Founded 2024 · $280.0M raised

Headquarters
San Francisco
Employees
1–10
Founded
2024
Total Funding
$280.0M
Last Round
$115.0M Series BAug 2026
Rounds
3

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Expedition Therapeutics develops treatments for inflammatory and respiratory diseases, with an initial focus on chronic obstructive pulmonary disease (COPD). Its lead program, EXPD-101, is an oral, once-daily DPP1 inhibitor designed to block neutrophil serine protease activation and address neutrophilic inflammation without depleting neutrophils. The company is advancing the candidate into a global Phase 2 COPD trial and sees further potential in bronchiectasis, neutrophilic asthma, and other neutrophil-driven diseases.

Summary

Expedition Therapeutics is a Biotech company based in San Francisco, United States, founded in 2024. It has raised $280.0M in total across 3 rounds, most recently a $115.0M Series B round in Aug 2026. Investors include General Atlantic, Sofinnova Investments and Novo Holdings A/S.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BAug 2026
$115.0M

Sign up to see all 3 events

Funding: Seed through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Expedition Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/expedition-therapeutics"><img src="https://indexed.vc/api/badge/company/expedition-therapeutics" alt="Expedition Therapeutics on Indexed.vc" width="260" height="76" /></a>